A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®)

ClinicalTrials.gov · COMPLETED, 2013

100 participants

Abstract

The primary objective is to evaluate the safety and tolerability of natalizumab (BG00002, Tysabri®) in the study population (Russian participants with relapsing remitting multiple sclerosis). The secondary objectives are to look at evaluation of severity of relapse, hospitalization and steroid use requirement; Expanded Disability Status Scale (EDSS), functional tests, quality of life self-assessment questionnaires including the short form health survey self-assessment questionnaire (SF-36) and multiple sclerosis impact scale 29 (MSIS-29), evidence of MRI disease activity, participants free of disease activity (clinical activity and/MRI activity) and anti JC Virus (JCV) antibody evaluation.

Conditions: Relapsing-Remitting Multiple Sclerosis.

Primary outcome: Number of participants that experience Serious Adverse Events (SAEs) and adverse events (AEs).

Enrollment: 100 participants.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 100 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• ClinicalTrials.gov
• Publisher page

Related studies

• A Survey on Knowledge Graphs: Representation, Acquisition, and Applications IEEE Transactions on Neural Networks and Learning Systems, 2021
• Toxicity of nanomaterials Chemical Society Reviews, 2011
• The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies Human Genetics, 2017
• Halogen bonding (X‐bonding): A biological perspective Protein Science, 2012
• Biofilm formation at the air–liquid interface by the Pseudomonas fluorescens SBW25 wrinkly spreader requires an acetylated form of cellulose Molecular Microbiology, 2003
• Opioid Activation of Toll-Like Receptor 4 Contributes to Drug Reinforcement Journal of Neuroscience, 2012

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free